Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cardiovascular disease (3) 3
cardiovascular diseases (3) 3
glucagon (3) 3
agonists (2) 2
base-line (2) 2
blood pressure (2) 2
cerebral infarction (2) 2
diabetes (2) 2
diabetes mellitus (2) 2
disease control (2) 2
glucagon-like peptide 1 (2) 2
health risk assessment (2) 2
health risks (2) 2
heart attacks (2) 2
hemoglobin (2) 2
incidence (2) 2
liraglutide (2) 2
medicine, general & internal (2) 2
motivation (2) 2
myocardial infarction (2) 2
peptides (2) 2
randomization (2) 2
risk analysis (2) 2
risk factors (2) 2
stroke (2) 2
abridged index medicus (1) 1
acute coronary syndrome - drug therapy (1) 1
acute coronary syndromes (1) 1
aged (1) 1
analysis (1) 1
angina pectoris (1) 1
angiotensin-converting enzyme inhibitors (1) 1
antianginal agents (1) 1
association (1) 1
blood-glucose (1) 1
cancer therapies (1) 1
cardiac & cardiovascular systems (1) 1
cardiovascular (1) 1
cardiovascular outcomes (1) 1
cholesterol (1) 1
clinical trials (1) 1
control methods (1) 1
coronary heart disease (1) 1
creatinine (1) 1
disease (1) 1
double-blind (1) 1
double-blind method (1) 1
drug dosages (1) 1
efficacy (1) 1
elderly (1) 1
elevation myocardial-infarction (1) 1
endocrinology & metabolism (1) 1
enzymes (1) 1
epidermal growth factor receptors (1) 1
events (1) 1
evolocumab (1) 1
exenatide twice (1) 1
female (1) 1
gastrointestinal surgery (1) 1
genetic-variants (1) 1
glomerular filtration (1) 1
glucagon-like peptide 1 - agonists (1) 1
glucose control (1) 1
guidelines (1) 1
heart-failure (1) 1
humans (1) 1
hypoglycemia (1) 1
incretin (1) 1
index medicus (1) 1
kidney diseases (1) 1
kidneys (1) 1
lixisenatide (1) 1
male (1) 1
microvasculature (1) 1
middle age (1) 1
middle aged (1) 1
mortality (1) 1
myocardial-infarction (1) 1
once-daily lixisenatide (1) 1
p38 mitogen-activated protein kinases - antagonists & inhibitors (1) 1
p38 mitogen-activated protein kinases - metabolism (1) 1
pcsk9 (1) 1
peptide-1 receptor agonists (1) 1
peptides - pharmacology (1) 1
peptides - therapeutic use (1) 1
placebos (1) 1
population studies (1) 1
protein kinase inhibitors - therapeutic use (1) 1
randomized clinical-trials (1) 1
receptor agonist lixisenatide (1) 1
renal replacement therapy (1) 1
reperfusion injury (1) 1
research design (1) 1
risk (1) 1
safety (1) 1
statin therapy (1) 1
therapy (1) 1
thyroid cancer (1) 1
type 2 diabetes (1) 1
type-2 diabetes-mellitus (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
by Gerstein, Hertzel C and Colhoun, Helen M and Dagenais, Gilles and Dagenais, Gilles R and Diaz, Rafael and Diaz, Sarahy and Lakshmanan, Mark and Pais, Prem and Probstfield, Jeffrey and Riesmeyer, Jeffrey S and Riddle, Matthew C and Rydén, Lars and Xavier, Denis and Atisso, Charles Messan and Dyal, Leanne and Hall, Stephanie and Hall, Charles and Rao-Melacini, Purnima and Wong, Gloria and Avezum, Alvaro and Basile, Jan and Chung, Ming-Min and Chung, Namsik and Chung, Jin-Wook and Conget, Ignacio and Cushman, William C and Franek, Edward and Hancu, Nicolae and Hanefeld, Christoph and Hanefeld, Markolf and Holt, Shaun and Jansky, Petr and Keltai, Matyas and Keltai, Katalin and Lanas, Fernando and Leiter, Lawrence A and Lopez-Jaramillo, Patricio and Cardona Munoz, Ernesto German and Pirags, Valdis and Pogosova, Nana and Raubenheimer, Peter J and Shaw, Jonathan E and Sheu, Wayne H-H and Temelkova-Kurktschiev, Theodora and Abella, Mercedes and Alebuena, Andrea and Almagro, Sandra and Amoroso, Eduardo and Anadon, Paula and Andreu, Elizabeth and Aristimuño, Guillermo and Arzadun, Maria and Barbieri, Maria and Barcudi, Raul and Bartolacci, Ines and Bolobanich, Gabriel and Bordonava, Anselmo and Bustamante Labarta, Miguel and Bustos, Betina and Caccavo, Alberto and Camino, Alejandra and Cantero, Maria and Carignano, Maria and Cartasegna, Luis and Cipullo, Marcela and Commendatore, Víctor and Conosciuto, Victoria and Costamagna, Osvaldo and Crespo, Claudia and Cuello, Jose and Cuneo, Carlos and Cusimano, Sandra and Dean, Sofia and Dituro, Claudio and Dominguez, Andrea and Farah, Miguel and Fernandez, Alberto and Fernandez, Florencia and Ferrari, Adriana and Flammia, Patricia and Fuentealba, Jose and Gallardo, Karina Beatriz and Garcia, Mar and Garcia, Celso and Garcia, Maria and Garcia Duran, Ruben and Garrido, Marcelo and Gavicola, Rodolfo and Gerbaudo, Claudio and Gilli, Graciela and Giotto, Ana Paula and Godoy Bolzán, Pedro and Gomez Vilamajo, Oscar and Guerlloy, Fernando and Guridi, Cristian and Gutierrez Garrido, Narcisa and Hasbani, Eduardo and Hermida, Sonia and Hominal, Miguel and Hrabar, Adrian and ... and REWIND Investigators
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk... 
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
by Gerstein, Hertzel C and Colhoun, Helen M and Dagenais, Gilles and Dagenais, Gilles R and Diaz, Rafael and Diaz, Sarahy and Lakshmanan, Mark and Pais, Prem and Probstfield, Jeffrey and Botros, Fady T and Riddle, Matthew C and Rydén, Lars and Xavier, Denis and Atisso, Charles Messan and Dyal, Leanne and Hall, Stephanie and Hall, Charles and Rao-Melacini, Purnima and Wong, Gloria and Avezum, Alvaro and Basile, Jan and Chung, Ming-Min and Chung, Namsik and Chung, Jin-Wook and Conget, Ignacio and Cushman, William C and Franek, Edward and Hancu, Nicolae and Hanefeld, Christoph and Hanefeld, Markolf and Holt, Shaun and Jansky, Petr and Keltai, Matyas and Keltai, Katalin and Lanas, Fernando and Leiter, Lawrence A and Lopez-Jaramillo, Patricio and Cardona Munoz, Ernesto German and Pirags, Valdis and Pogosova, Nana and Raubenheimer, Peter J and Shaw, Jonathan E and Sheu, Wayne H-H and Temelkova-Kurktschiev, Theodora and Abella, Mercedes and Alebuena, Andrea and Almagro, Sandra and Amoroso, Eduardo and Anadon, Paula and Andreu, Elizabeth and Aristimuño, Guillermo and Arzadun, Maria and Barbieri, Maria and Barcudi, Raul and Bartolacci, Ines and Bolobanich, Gabriel and Bordonava, Anselmo and Bustamante Labarta, Miguel and Bustos, Betina and Caccavo, Alberto and Camino, Alejandra and Cantero, Maria and Carignano, Maria and Cartasegna, Luis and Cipullo, Marcela and Commendatore, Víctor and Conosciuto, Victoria and Costamagna, Osvaldo and Crespo, Claudia and Cuello, Jose and Cuneo, Carlos and Cusimano, Sandra and Dean, Sofia and Dituro, Claudio and Dominguez, Andrea and Farah, Miguel and Fernandez, Alberto and Fernandez, Florencia and Ferrari, Adriana and Flammia, Patricia and Fuentealba, Jose and Gallardo, Karina Beatriz and Garcia, Mar and Garcia, Celso and Garcia, Maria and Garcia Duran, Ruben and Garrido, Marcelo and Gavicola, Rodolfo and Gerbaudo, Claudio and Gilli, Graciela and Giotto, Ana Paula and Godoy Bolzán, Pedro and Gomez Vilamajo, Oscar and Guerlloy, Fernando and Guridi, Cristian and Gutierrez Garrido, Narcisa and Hasbani, Eduardo and Hermida, Sonia and Hominal, Miguel and Hrabar, Adrian and ... and REWIND Investigators
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 131 - 138
Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the... 
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
by Bentley-Lewis, Rhonda, MD and Aguilar, David, MD and Riddle, Matthew C., MD and Claggett, Brian, PhD and Diaz, Rafael, MD and Dickstein, Kenneth, MD, PhD and Gerstein, Hertzel C., MD and Johnston, Peter, MD and Køber, Lars V., MD and Lawson, Francesca, MD and Lewis, Eldrin F., MD and Maggioni, Aldo P., MD and McMurray, John J.V., MD and Ping, Lin, MD and Probstfield, Jeffrey L., MD and Solomon, Scott D., MD and Tardif, Jean-Claude, MD and Wu, Yujun, PhD and Pfeffer, Marc A., MD, PhD and ELIXA Investigators
American Heart Journal, ISSN 0002-8703, 2015, Volume 169, Issue 5, pp. 631 - 638.e7
Background Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients... 
Cardiovascular | EXENATIDE TWICE | CARDIAC & CARDIOVASCULAR SYSTEMS | GLUCOSE CONTROL | ONCE-DAILY LIXISENATIDE | REPERFUSION INJURY | HEART-FAILURE | DOUBLE-BLIND | RECEPTOR AGONIST LIXISENATIDE | RANDOMIZED CLINICAL-TRIALS | TYPE-2 DIABETES-MELLITUS | ELEVATION MYOCARDIAL-INFARCTION | Cardiovascular Diseases | Double-Blind Method | Humans | Middle Aged | Male | Peptides - pharmacology | Acute Coronary Syndrome - drug therapy | Glucagon-Like Peptide 1 - agonists | Protein Kinase Inhibitors - therapeutic use | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Placebos | Female | Aged | p38 Mitogen-Activated Protein Kinases - metabolism | Research Design | Peptides - therapeutic use | Type 2 diabetes | Glucagon | Coronary heart disease | Analysis | Cardiovascular disease | Heart attacks | Acute coronary syndromes | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights